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The leukotrienes (LTs) are a family of lipid-derived autacoids
that originate from arachidonic acid (AA). 5-Lipooxygenase (5-
LO) is the key enzyme in this process. It transforms AA through
a two-step process, first into 5-hydroperoxyeicosatetraenoic
acid (5-HPETE), and then into unstable leukotriene A4 (LTA4).
This intermediate can be transformed either by leukotriene B4
synthase into leukotriene B4 (LTB4), or by leukotriene C4 syn-
thase, which is a specific glutathione transferase, into peptide–
lipid leukotrienes C4, D4, and E4 (LTC4, LTD4, LTE4).
[1–3] LTs are in-
volved in a variety of inflammatory and allergic disorders, par-
ticularly rheumatoid arthritis and inflammatory skin and bowel
diseases. They also display potent bronchoconstrictor activity.
Consequently, the treatment of allergic disorders and asthma
are the classical indications for 5-LO inhibitors.[4, 5] Novel and in-
teresting potential indications are emerging for these prod-
ucts; for example, an increasing amount of experimental evi-
dence shows an involvement of the 5-LO pathway in tumor
cell proliferation.[5] In particular, inhibition of 5-LO was found
to induce apoptosis in various cancer cell types.[6] The evidence
that LTs are involved in atherogenesis and arterial wall remod-
eling sets the stage for new strategies in treating the develop-
ment and progression of atherosclerosis.[5, 7, 8] 5-LO inhibitors
can be classified into four different classes according to their
mechanism of action: redox-active compounds, competitive re-
versible inhibitors, inhibitors of 5-LO activating protein (FLAP),
and iron-chelating inhibitors. Many substances that belong to
these classes were developed as potent 5-LO inhibitors, includ-
ing natural products.[9–11] Among them, only ( )-[1-(1-benzo[b]-
thien-2-yl)ethyl]-1-hydroxyurea (1, zileuton), a hydroxyurea de-
rivative of the iron-ligand-type in-
hibitor class, entered into the
market in 1996 as an anti-asthmat-
ic drug.[12,13] The commercially
available product is a racemic mix-
ture of R and S enantiomers, both
of which display in vitro 5-LO in-
hibitor activity.
A number of studies have been carried out in recent years
to design 5-LO inhibitors with dual activity: 5-LO/cyclooxyge-
nase (COX) inhibitors have received particular attention as anti-
inflammatory agents, and compounds either with dual 5-LO/
thromboxane A2 synthase inhibitory activity or with 5-LO inhib-
itor and platelet-activating factor (PAF) receptor antagonist
mixed properties have also been developed.[10] These are ex-
amples of multitarget drugs, which should be able to modu-
late more than one target simultaneously; their development
represents an alternative approach to using drug cocktails es-
pecially in the treatment of complex diseases such as athero-
sclerosis and inflammation. The most common strategy to
obtain these products is the combination of two appropriate
drugs, or their crucial parts, into a single molecule.[14] To our
knowledge there has not yet been any documented examples
of nitric oxide (NO) donor/5-LO inhibitor hybrids, despite the
clear interest in such a combination. Indeed, NO is a physiolog-
ical messenger that triggers a variety of actions in different sys-
tems.[15] In particular, it plays very important roles in the cardio-
vascular system in maintaining a number of homeostatic re-
sponses: preservation of endothelial integrity, arterial blood
vessel dilation including pulmonary arterial vasculature, inhibi-
tion of platelet adherence and aggregation, attenuation of leu-
kocyte adherence, and activation and inhibition of vascular
smooth muscle cell proliferation.[16] NO also triggers relevant
action in airways, inducing relaxation of airway smooth
muscle, pro-inflammatory or anti-inflammatory effects, and
regulation of mucociliary clearance.[17] The use of NO donors in
the treatment of cardiovascular disease (CD) is well known,
while the therapeutic potential of these kinds of products in
the field of respiratory disease is still under examination.[16–19]
Herein we propose new dual-action products, obtained by
combining zileuton with NO donor nitrooxy or furoxan moiet-
ies.
The synthesis of the final products required the preliminary
preparation of a number of intermediates (Scheme 1). The sub-
stituted benzothiophene 3 was easily obtained by treating 6-
hydroxybenzothiophene (2) with n-butyllithium and anhydrous
acetaldehyde in THF at 20 8C. The triflates 8–11 were pre-
pared by the action of trifluoromethanesulfonyl anhydride in
dichloromethane on the appropriate nitrooxy-substituted alco-
hols 4–7 in the presence of 2,6-lutidine at 40 8C and were im-
mediately used. Treatment of 3 with sodium hydride in THF,
followed by the appropriate triflates 8–11 in dichloromethane
afforded the expected nitrates 14–17. The action of 37% hy-
drochloric acid on these products dissolved in THF/water in
the presence of hydroxyurea at 50 8C afforded the target com-
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pounds 18–21. The furoxan derivatives 22 and 23 were pre-
pared by reaction of 3 with the respective 4-bromomethylfur-
oxans 12 or 13 in dry DMF in the presence of potassium car-
bonate. The final furoxan models 24 and 25 were obtained
from 22 and 23 by following the same procedure used to pre-
pare the analogous nitric esters 18–21 from 14–17.
The ability of the target products 18–21, 24, 25, and of the
reference compound zileuton to inhibit 5-LO was assessed by
incubating each compound in heparin-treated human whole
blood. After a fixed time, LT biosynthesis was initiated by addi-
tion of the calcium ionophore
A23187, and terminated by rapid
cooling of the blood. After cen-
trifugation, the plasma level of
LTB4 was analyzed by enzyme-
linked immunosorbent assay
(ELISA). All the products were
able to inhibit LTB4 production
in a concentration-dependent
manner. The potencies of inhibi-
tion, expressed as IC50, cover the
concentration range of 2–18 mm
(Table 1). Detailed data analysis
shows that the most potent in-
hibitor is the mononitrooxy-sub-
stituted compound 18. Its IC50
value is same as that of zileuton,
within experimental error. The
inhibitory activity still good, but
a bit lower for homologue 19, in
which the length of the nitrooxy-
alkoxy lateral chain is increased.
The dinitrooxy-substituted com-
pound 20 is also nearly equipo-
tent to zileuton, and this activity
is largely retained in its higher
homologue 21. The furoxancar-
boxamide 25 is the least active
of the series, with a potency
about tenfold lower than that of
zileuton, whereas its methyl ana-
logue 24 is only fourfold less
potent than the reference. Alto-
gether, these data indicate that
hybridization of zileuton with
appropriate NO donor moieties
affords compounds with good
levels of 5-LO inhibition.
The myorelaxation effects of
the target products were as-
sessed on rat tracheal rings pre-
contracted with 1 mm carbachol.
All the products were capable of
relaxing the contracted tissue in
a concentration-dependent
manner, and the maximum re-
sponse was determined with
()-isoprenaline at 10 mm. The potencies of the products, ex-
pressed as EC50, are listed in Table 1; these figures fall in the
narrow concentration range of 15–37 mm. In the nitric acid
ester series, the mononitrooxy derivatives 18 and 19 display
the same activity and are half as potent as the equipotent dini-
trooxy analogues 20 and 21. Between the two furoxan deriva-
tives, only the furoxancarboxamide 25 shows an EC50 value in
the micromolar range, while the methyl-substituted furoxan 24
does not elicit any myorelaxing effect when tested up to
30 mm. As expected, zileuton also does not trigger any effect
Scheme 1. Reagents and conditions: a) nBuLi, acetaldehyde, THF (anhyd), 20 8C; b) trifluoromethanesulfonyl an-
hydride, 2,6-lutidine, CH2Cl2 (anhyd), 40 8C, N2; c) NaH, THF (anhyd), 10 8C, N2, 8–11 dissolved in CH2Cl2 (anhyd);
d) 12 or 13, K2CO3, DMF (anhyd), RT; e) hydroxyurea, HCl (37%), H2O/THF, 50 8C.
Table 1. Vasodilation, myorelaxation, and 5-LO inhibition properties of zileuton (1) and compounds 18–21, 24,
and 25.
Compd R Vasodilation[a] Myorelaxation[b] 5-LO Inhibition[c]
EC50SE [mm]
(+ODQ 1 mm)
EC50SE [mm]
(+ODQ 10 mm)
IC50 [mm]
(95% CL)
1 H –[d] –[d] 1.6 (1.3–2.0)
18 0.0390.007 (>30) 375 (–[d]) 2.0 (1.6–2.5)
19 0.0230.003 (>30) 368 (–[d]) 5.8 (4.3–7.7)
20 0.0150.004 (233) 163 (–[d]) 2.8 (2.0–4.1)
21 0.0270.004 (144) 151 (–[d]) 3.5 (2.8–4.3)
24 282 (–[d]) –[d] 6.3 (4.9–8.3)
25 0.180.04 (6.40.7) 242 (–[d]) 17.9 (11.5–28.0)
[a] Determined on rat thoracic aorta pre-contracted with 1 mm phenylephrine. [b] Determined on rat tracheal
rings pre-contracted with 1 mm carbachol. [c] Measured as the ability of the compound to inhibit biosynthesis
of LTB4 in human whole blood challenged with the calcium ionophore A23187. [d] Inactive at the maximum
concentration tested (30 mm).
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on the contracted tissue, suggesting that the myorelaxing ef-
fects observed for all the active products are mediated by NO.
To confirm this hypothesis, the activity of the products on pre-
contracted tracheal rings was assessed in the presence of
10 mm 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a
well-known inhibitor of soluble guanylate cyclase (sGC). This is
the key enzyme in mediating tracheal relaxation induced by
NO and NO-related compounds through elevation of the intra-
cellular concentration of guanosine 3’,5’-cyclic monophosphate
(cGMP).[20] The suppression of sGC activity, when the products
were tested up to a concentration of 30 mm, is in keeping with
the involvement of the NO messenger in their myorelaxing
action. The NO-dependent myorelaxing potency of the prod-
ucts is near their 5-LO inhibition potency range. This means
that the hybrids display these two activities in vitro in a fairly
well-balanced manner.
The vasodilator effects of the target hybrids were assessed
with denuded rat aorta strips pre-contracted with phenylephr-
ine. The vasodilator potencies of the products, expressed as
EC50, are also listed in Table 1. The nitrooxy-substituted com-
pounds are very potent vasodilators, with EC50 values in the
sub-micromolar range. In the nitric ester series, the products
display similar potencies, ranked in the order: 20>1921>
18. The furoxancarboxamide 25 is also quite a potent vasodila-
tor, about tenfold less potent than dinitrooxy ester 20, the
most potent derivative of the series, and 150-fold more potent
than the methyl furoxan 24. The significant decrease in activi-
ties observed when the experiments were repeated in the
presence of 1 mm ODQ is in keeping with a NO-mediated vaso-
dilator mechanism. Altogether, these data indicate that in vitro
NO-mediated vasodilator effects of the tested compounds
dominate their 5-LO inhibitor capacity. The only exception is
methylfuroxan 24, for which these two activities occur at simi-
lar concentrations.
All the target products, including zileuton (1) as reference,
were tested on carrageenan-induced paw edema in conscious
rats. The injection of carrageenan into the hind paw produced
swelling, which reached its maximum at 5–6 h. Zileuton
(30 mgkg1 i.g.) significantly decreased paw edema at 3, 4, and
5 h from carrageenan injection. Maximum inhibition was ach-
ieved at 3 h: 41.015.40% relative to corresponding control
values. The inhibitory activity of the compound was well main-
tained throughout the duration of the experiment (Figure 1).
This is in line with previous data showing that both 5-LO inhib-
itors and LT receptor antagonists are effective against carra-
geenan-induced inflammation and pain.[21,22] The inflammatory
reaction to carrageenan involves activation of neutrophils and
mast cells, both of which are the predominant source of che-
motactic LTB4 and peptide–leukotrienes.
[23,24] Compound 18,
administered at a dose (45.12 mgkg1 i.g.) equimolar to zileu-
ton, induced a significant inhibition of paw edema, displaying
the same activity as the lead (Figure 1). Compound 25
(49.94 mgkg1 i.g.) significantly decreased (~20%) edema at
4 h only, while at the other time points it showed a trend
toward inhibition, although its effect did not reach statistical
significance. All the other analogues proved to be ineffective.
The dose dependence of the activity of zileuton in the carra-
geenan-induced paw edema test[22] indicates that higher doses
of the present series of zileuton analogues should be tested.
However, these experiments were precluded by the low solu-
bility of the products in the vehicle (Figure 1).
Notably, while the compounds at the doses tested differ in
their anti-inflammatory activity, they display similar in vitro 5-
LO inhibition potency, suggesting a different pharmacokinetic
profile between the compounds.
In conclusion, a number of hitherto unknown hybrid prod-
ucts, obtained by combining zileuton with either NO donor ni-
trooxy or furoxan moieties, were designed and evaluated as
dual 5-LO inhibitors, rat tracheal ring myorelaxing agents, and
vasodilators of rat aorta strips pre-contracted with phenylephr-
ine. The products display 5-LO inhibitory activity in the micro-
molar range, close to where NO-dependent myorelaxing ef-
fects are observed. In contrast, their NO-dependent vasodilator
effects occur in the sub-micromolar range, with the sole excep-
tion of the methyl-substituted furoxan derivative 24, which is
active at micromolar concentrations. Altogether, the in vitro re-
sults reported herein indicate that this new class of dual 5-LO
inhibitors/NO donors could find interesting applications in the
treatment of airway and inflammatory diseases, as well as in
the management of atherosclerosis development and its pro-
gression.
Preliminary characterization of in vivo pharmacological activ-
ity showed that compound 18, namely zileuton substituted at
the 6-position with the simple 3-nitrooxypropyloxy chain, ex-
hibits anti-inflammatory activity near that of the lead 1, when
tested in the carrageenan-induced rat paw edema assay. Com-
pound 25, bearing a (3-carbamoylfuroxan-4-yl)methoxy group
at the 6-position, also displays significant activity after 4 h. Be-
cause solubility limitations preclude administration of higher
doses in this experimental model, additional in vivo studies are
necessary to fully evaluate the potential of this series of com-
pounds.
Figure 1. Percent increase in carrageenan-induced paw edema in rat. The
compounds were administered by intragastric route at doses equimolar
with zileuton 1, (30 mgkg1), and their effects were evaluated at 2, 3, 4, and
5 h from carrageenan injection; **p<0.01, *p<0.05 vs. control (Dunnett’s
test).
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Experimental Section
Melting points (mp) were measured on a capillary apparatus (Bchi
540); mp with decomposition were determined after placing the
sample in a bath at a temperature 10 8C below the mp; a heating
rate of 3 8Cmin1 was used. All compounds were routinely checked
by FTIR (PerkinElmer SPECTRUM BXII), 1H and 13C NMR (Bruker
Avance 300), and mass spectrometry (Finnigan-Mat TSQ-700). Flash
column chromatography was performed on silica gel (Merck Kiesel-
gel 60, 230–400 mesh ASTM) using the eluents indicated. Thin-
layer chromatography (TLC) was carried out on 520 cm plates
with 0.25 mm layer thickness. Anhydrous MgSO4 was used as
drying agent for the organic phases. Analysis (C, H, N) of the new
compounds was performed by REDOX (Monza): the results are
within 0.4% of theoretical values. Compounds 2,[25] 4,[26] 5,[26]
6,[27] 7,[28] 12,[29] and 13[29] were synthesized by following published
methods. Tetrahydrofuran (THF) was distilled immediately before
use from sodium and benzophenone.
1-(6-Hydroxybenzo[b]thiophen-2-yl)ethanol (3). nBuLi (1.6m in
hexane, 25 mL, 3 equiv) was added at <20 8C to a stirred solu-
tion of compound 2 (2.00 g, 13 mmol) in anhydrous THF (80 mL)
under N2, and the mixture was stirred for 3 h at 0 8C. Anhydrous
acetaldehyde (1.72 g, 2.2 mL, 40 mmol) was then added below
20 8C, and the solution was allowed to warm to room tempera-
ture over 2 h. The mixture was quenched with saturated NH4Cl
(80 mL). After separation of the layers, the aqueous layer was ex-
tracted with EtOAc (375 mL). The combined organic layers were
washed with H2O (50 mL) and brine (30 mL), dried over anhydrous
MgSO4, and concentrated under reduced pressure. The residue was
purified by flash chromatography (CH2Cl2/EtOAc 9:1) to give 1.00 g
of unreacted starting compound 2 and 1.26 g of the title com-
pound 3 as a white solid (1.26 g, 50%): mp: 146–147 8C (dec.) ;
1H NMR (300 MHz, [D6]DMSO): d=1.44 (d,
3J=6 Hz, 3H, CH3), 4.94
(m, 1H, CH), 5.56 (d, 1H, 3J=5 Hz, OH), 6.81 (dd, 1H, 4J=2 Hz, 3J=
9 Hz, H-5), 7.04 (s, 1H, H-3), 7.19 (d, 1H, 4J=2 Hz, H-7) 7.52 (d, 1H,
3J=9 Hz, H-4), 9.46 ppm (s, 1H, 6-OH) ; 13C NMR (75 MHz,
[D6]DMSO): d=25.1, 64.4, 106.9, 113.8, 117.8, 123.5, 131.9, 139.7,
148.3, 154.2 ppm; IR (KBr): n˜=3376, 1611, 1571, 1542, 1429, 1349,
1257, 1216, 1150, 1073, 1048, 1004, 985, 915, 848, 806 cm1; MS (EI,
70 eV) m/z (%): 194 (94) [M]+ , 179 (94), 151 (100); Anal. calcd for
C10H10O2S (194.25): C 61.83, H 5.19; found: C 61.87, H 5.23.
General method for the preparation of triflates 8–11. Trifluoro-
methanesulfonyl anhydride (0.44 mL, 2.6 mmol, 1.3 equiv) was
added dropwise to a solution of the appropriate nitrate 4–7
(2 mmol, 1.0 equiv) and 2,6-lutidine (0.30 mL, 2.6 mmol, 1.3 equiv)
in CH2Cl2 (anhyd, 10 mL) at 40 8C under N2, and the resulting so-
lution was stirred at this temperature for 1 h. The solution was
then filtered on a small pad of silica gel (eluent CH2Cl2) and evapo-
rated under vacuum to give an oil that was immediately used in
the next step.
3-({2-[1-Carbamoyl(hydroxyamino)ethyl]-1-benzo[b]thiophen-6-
yl}oxy)propyl nitrate (18). NaH (60% in mineral oil, 78 mg,
1.95 mmol, 1.3 equiv) was added portion-wise to a solution of 3
(291 mg, 1.5 mmol, 1.0 equiv) in THF (anhyd, 5 mL), under N2 at
15 8C, and the solution was stirred until no more gas developed.
A solution of triflate 8 (506 mg, 2 mmol, 1.3 equiv) in anhydrous
CH2Cl2 was added to this solution via gas-tight syringe. The reac-
tion mixture was stirred at 15 8C for 30 min, and then it was
quenched with saturated NH4Cl. After separation of the layers, the
aqueous layer was extracted with EtOAc. The combined organic
layers were washed with H2O and brine, dried over anhydrous
MgSO4, and concentrated under reduced pressure. The residue was
purified by flash chromatography (PE/EtOAc 8.5:1.5) to give 3-{[2-
(1-hydroxyethyl)-1-benzothien-6-yl]oxy}propyl nitrate (14) as a
transparent oil that was used in the next step (54%); 1H NMR
(300 MHz, [D6]DMSO): d=1.47 (d,
3J=6 Hz, 3H, CH3), 2.21–2.12 (m,
2H, CCH2C), 4.11 (t,
3J=6 Hz, 2H, CH2OC), 4.71 (t,
3J=6 Hz, 2H,
CH2ON), 5.01–4.94 (m, 1H, CHO), 5.63 (d,
3J=5 Hz, 1H, OH), 6.94
(dd, 4J=2 Hz, 3J=9 Hz, 1H, H-5), 7.11 (s, 1H, H-3), 7.49 (d, 4J=2 Hz,
1H, H-7) 7.63 ppm (d, 3J=9 Hz, 1H, H-4) ; 13C NMR (75 MHz,
[D6]DMSO): d=25.8, 26.7, 64.7, 65.1, 71.4, 106.4, 114.6, 118.6, 124.3,
133.9, 140.3, 150.6, 155.9 ppm.
A solution of hydroxyurea (112 mg, 1.5 mmol, 1.5 equiv) in H2O
(7 mL) was added to a solution of 14 (300 mg, 1.0 mmol, 1 equiv)
in THF (10 mL), and this reaction mixture was warmed to 50 8C. HCl
(37%, 3.00 g, 2.61 mL, 30 mmol, 30 equiv) was then added. The re-
action mixture was warmed to 50 8C for 1.5 h, and was then
quenched with saturated NH4Cl. After separation of the layers, the
aqueous layer was extracted with EtOAc. The combined organic
layers were washed with H2O and brine, dried over anhydrous
MgSO4, and concentrated under reduced pressure. The residue was
purified by flash chromatography (CH2Cl2/iPrOH 7:3) to give 18 as
a white solid (309 mg, 58%): mp: 153–156 8C (dec. , MeOH);
1H NMR (300 MHz, [D6]DMSO): d=1.48 (d,
3J=7 Hz, 3H, CH3), 2.20–
2.12 (m, 2H, CCH2C), 4.11 (t,
3J=6 Hz, 2H, CH2OC), 4.70 (t,
3J=6 Hz,
2H, CH2ON), 5.51 (q,
3J=7 Hz, 1H, CHCH3), 6.43 (s, 2H, NH2), 6.94
(dd, 4J=2 Hz, 3J=9 Hz, 1H, H-5), 7.15 (s, 1H, H-3), 7.47 (d, 4J=2 Hz,
1H, H-7) 7.64 (d, 3J=9 Hz, 1H, H-4), 9.19 ppm (s, 1H, OH) ; 13C NMR
(75 MHz, [D6]DMSO): d=17.9, 26.4, 52.4, 64.4, 71.1, 105.9, 114.3,
120.9, 124.0, 133.2, 140.6, 143.5, 155.8, 161.5 ppm; IR (KBr): n˜=
3462, 3186, 2891, 1654, 1609, 1542, 1460, 1290, 1263, 1215, 1153,
1091, 1059, 956, 838 cm1; MS (EI, 70 eV) m/z (%): 355 (1) [M]+ , 338
(7), 280 (37), 234 (49), 176 (100); Anal. calcd for C14H17N3O6S
(355.37): C 47.32, H 4.82, N 11.82; found: C 47.52, H 4.84, N 11.84.
6-({2-[1-Carbamoyl(hydroxyamino)ethyl]-1-benzo[b]thiophen-6-
yl}oxy)hexyl nitrate (19). The title compound was obtained as was
18 by starting from 9, with the only difference that the intermedi-
ate 15 was directly used, without further purification, in the reac-
tion with hydroxyurea. The title compound was purified by flash
chromatography (PE/EtOAc 8:2) to give a white solid (37%): mp:
135–136 8C (dec. , EtOAc); 1H NMR (300 MHz, [D6]DMSO): d=1.26–
1.45 (m, 4H), 1.65–1.76 (m, 4H) (CH2 chain), 1.48 (d,
3J=7 Hz, 3H,
CH3), 4.02 (t,
3J=6 Hz, 2H, CH2OC), 4.52 (t,
3J=6 Hz, 2H, CH2ON),
5.51 (q, 3J=7 Hz, 1H, CHCH3), 6.43 (s, 2H, NH2), 6.93 (dd,
4J=2 Hz,
3J=9 Hz, 1H, H-5), 7.13 (s, 1H, H-3), 7.43 (d, 4J=2 Hz, 1H, H-7) 7.63
(d, 3J=9 Hz, 1H, H-4), 9.19 ppm (s, 1H, OH) ; 13C NMR (75 MHz,
[D6]DMSO): d=17.7, 24.7, 25.0, 25.9, 28.4, 52.2, 67.5, 73.7, 105.5,
114.1, 120.7, 123.7, 132.7, 140.4, 143.0, 155.9, 161.3 ppm; IR (KBr):
n˜=3463, 3321, 3177, 2989, 2939, 1657, 1572, 1543, 1470, 1388,
1367, 1280, 1263, 1215, 1153, 1081, 1025, 992, 950, 870, 838 cm1;
MS (EI, 70 eV) m/z (%): 397 (1) [M]+ , 380 (3), 352 (20), 307 (40), 207
(90), 176 (100); Anal. calcd for C17H23N3O6S (397.45): C 51.37, H 5.83,
N 10.57; found: C 51.28, H 5.89, N 10.49.
4-({2-[1-Carbamoyl(hydroxyamino)ethyl]-1-benzo[b]thiophen-6-
yl}oxy)buthan-1,2-diyl dinitrate (20). The title compound was ob-
tained as was 19 by starting from 10, through the crude intermedi-
ate 16. The title product was purified by flash chromatography
(CH2Cl2/MeOH 9.8:0.2) to give a white solid (17%): mp: 115–116 8C
(dec. , EtOAc/hexane); 1H NMR (300 MHz, [D6]DMSO): d=1.48 (d,
3J=6 Hz, 3H, CH3), 2.22–2.25 (m, 2H, CCH2C), 4.04 (m, 2H, CH2OC),
4.80 (dd, 2J=13 Hz, 3J=6 Hz, 1H, CH2ON), 5.02 (dd,
2J=13 Hz, 3J=
2 Hz, 1H, CH2ON), 5.51–5.53 (m, 1H, CHONO2), 5.66 (m, 1H, CHCH3),
6.43 (s, 2H, NH2), 6.93 (dd,
4J=2 Hz, 3J=9 Hz, 1H, H-5), 7.15 (s, 1H,
H-3), 7.47 (d, 4J=2 Hz, 1H, H-7), 7.64 (d, 3J=9 Hz, 1H, H-4),
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9.19 ppm (s, 1H, OH) ; 13C NMR (75 MHz, [D6]DMSO): d=17.7, 28.2,
52.2, 63.7, 72.0, 77.9, 105.7, 114.0, 120.7, 123.8, 133.1, 140.3, 143.4,
155.4, 161.3 ppm; IR (KBr): n˜=3480, 3350, 2941, 1659, 1646, 1601,
1578, 1466, 1273, 1227, 1150, 1064, 845 cm1; MS (EI, 70 eV) m/z
(%): 385 (17), 340 (30), 295 (27), 263 (100), 207 (75); Anal. calcd for
C15H18N4O9S (430.39): C 41.86, H 4.22, N 13.02; found: C 42.33, H
4.23, N 12.70.
6-({2-[1-Carbamoyl(hydroxyamino)ethyl]-1-benzo[b]thiophen-6-
yl}oxy)hexan-1,2-diyl dinitrate (21). The title compound was ob-
tained as was 19 by starting from 11, through the crude intermedi-
ate 17. The title compound was purified by flash chromatography
(CH2Cl2/EtOAc 7:3) to give a white solid (30%): mp: 105–107 8C
(dec. , EtOAc/hexane); 1H NMR (300 MHz, [D6]DMSO): d=1.48 (d,
3J=7 Hz, 3H, CH3), 1.54–1.60 (m, 2H) 1.73–1.83 (m, 4H), (CCH2C),
4.02 (t, 3J=6 Hz, 2H, CH2OC), 4.72 (dd,
2J=13 Hz, 3J=6 Hz, 1H,
CH2ON), 4.95 (dd,
2J=13 Hz, 3J=2 Hz, 1H, CH2ON), 5.42–5.47 (m,
1H, CHONO2), 5.50 (q,
3J=7 Hz, 1H, CHCH3), 6.43 (s, 2H, NH2), 6.93
(dd, 4J=2 Hz, 3J=9 Hz, 1H, H-5), 7.14 (s, 1H, H-3), 7.44 (d, 4J=2 Hz,
1H, H-7), 7.63 ppm (d, 3J=9 Hz, 1H, H-4) ; 13C NMR (75 MHz,
[D6]DMSO): d=17.7, 21.1, 27.9, 28.1, 52.2, 67,3, 71.9, 80.2, 105.5,
114.1, 120.7, 123.7, 132.8, 140.4, 143.1, 155.9, 161.3 ppm; IR (KBr):
n˜=3465, 3196, 2939, 2870, 1659, 1572, 1465, 1270, 1225, 1152,
844 cm1; MS (CI) m/z (%): 459 (1) [M+H]+ , 414 (100); Anal. calcd
for C17H22N4O9S (458.45): C 44.54, H 4.84, N 12.22; found: C 44.69,
H 4.80, N 11.98.
1-Hydroxy-1-(1-{6-[(4-methylfuroxan-3-yl)methoxy]benzo[b]hio-
phen-2-yl}ethanyl)urea (24). Compound 12 (289 mg, 1.5 mmol,
1.5 equiv) was added portion-wise to a solution of 3 (194 mg,
1.0 mmol, 1 equiv) and K2CO3 (552 mg, 4.0 mmol, 4.0 equiv) in N,N-
dimethylformamide (DMF; anhyd, 1.5 mL), and the reaction mixture
was stirred at room temperature for 1 h. Ice water was then added,
and the formed solid was triturated and filtered to give crude 22,
which was used directly in the next step. 1H NMR (300 MHz,
[D6]DMSO): d=1.47 (d,
3J=6 Hz, 3H, CH3), 2.20 (s, 3H, 4-CH3-fx),
5.00 (m, 1H, CH), 5.35 (s, 2H, CH2O), 5.68 (d,
3J=4 Hz, 1H, OH), 7.07
(dd, 4J=2 Hz, 3J=9 Hz, 1H, H-5), 7.15 (s, 1H, H-3), 7.67 (s, 1H, H-7),
7.70 ppm (s, 1H, H-4) ; 13C NMR (75 MHz, [D6]DMSO): d=7.4, 25.4,
61.1, 64.6, 107.0, 113.0, 114.3, 118.0, 123.9, 134.3, 139.7, 150.3,
154.4, 155.5 ppm; MS (EI, 70 eV) m/z (%): 306 (30) [M]+ , 288 (30),
193 (70), 175 (100).
A solution of hydroxyurea (112 mg, 1.5 mmol, 1.5 equiv) in H2O
(7 mL) was added to a solution of 22 (306 mg, 1.0 mmol, 1 equiv)
in THF (10 mL), and this reaction mixture was warmed to 50 8C. HCl
(37%, 3.00 g, 2.61 mL, 30 mmol, 30 equiv) was then added. The re-
action mixture was warmed to 50 8C for 2 h, and then concentrated
under reduced pressure; the formed solid was triturated and fil-
tered. The crude 24 was purified by crystallization from EtOAc/
hexane to give a white solid (146 mg, 40%): mp: 143–144 8C (dec. ,
EtOAc/hexane); 1H NMR (300 MHz, [D6]DMSO): d=1.49 (d,
3J=7 Hz,
3H, CH3), 2.19 (s, 3H, 4-CH3-fx), 5.35 (s, 2H, CH2O), 5.52 (q,
3J=7 Hz,
1H, CH), 6.44 (s, 2H, NH2), 7.07 (dd,
4J=2 Hz, 3J=9 Hz, 1H, H-5),
7.18 (s, 1H, H-3), 7.65 (d, 4J=2, 1H, H-7), 7.70 (d, 3J=9 Hz, 1H, H-4),
9.21 ppm (s, 1H, OH) ; 13C NMR (75 MHz, [D6]DMSO): d=7.6, 17.9,
52.4, 61.3, 107.0, 113.2, 114.4, 120.9, 124.1, 134.0, 140.4, 144.3,
154.8, 155.7, 161.5 ppm; IR (KBr): n˜=3482, 3340, 2826, 1664, 1628,
1578, 1475, 1375, 1258, 1229, 1150, 1026, 847 cm1; MS (CI) m/z
(%): 365 (40) [M+H]+ , 320 (100); Anal. calcd for C15H16N4O5S
(364.38): C 49.44, H 4.43, N 15.38; found: C 49.02, H 4.46, N 15.03.
4-({2-[1-Carbamoyl(hydroxyamino)ethyl]-1-benzo[b]thiophen-6-
yl}oxy)methylfuroxan-3-carboxamide (25). Compound 13
(222 mg, 1.5 mmol, 1.5 equiv) was added portion-wise to a solution
of 3 (194 mg, 1.0 mmol, 1 equiv) and K2CO3 (552 mg, 4.0 mmol,
4.0 equiv) in DMF (anhyd, 1.5 mL) and the reaction mixture was
stirred at room temperature for 1 h. Ice water was then added, and
after separation of the layers the aqueous layer was extracted with
EtOAc. The combined organic layers were washed with H2O and
brine, dried over anhydrous MgSO4, and concentrated under re-
duced pressure. The residue was purified by flash chromatography
(CH2Cl2/EtOAc 8:2) to give 23 as a white solid (201 mg, 60%):
1H NMR (300 MHz, [D6]DMSO): d=1.46 (d,
3J=6 Hz, 3H, CH3), 4.99
(m, 1H, CH), 5.46 (s, 2H, CH2O), 5.66 (d,
3J=5 Hz, 1H, OH), 7.06 (dd,
4J=2 Hz, 3J=9 Hz, 1H, H-5), 7.14 (s, 1H, H-3), 7.63 (d, 4J=2 Hz, 1H,
H-7), 7.66 (d, 3J=9 Hz, 1H, H-4), 7.85, 8.50 ppm (2 s, 2H, NH2) ;
13C NMR (75 MHz, [D6]DMSO): d=26.3, 62.5, 65.6, 107.7, 111.4,
115.2, 118.9, 124.8, 135.0, 140.7, 151.7, 155.7, 156.2, 156.6 ppm; MS
(EI, 70 eV) m/z (%): 335 (30) [M]+ , 317 (2), 193 (100), 175 (60).
A solution of hydroxyurea (112 mg, 1.5 mmol, 1.5 equiv) in H2O
(7 mL) was added to a solution of 23 (335 mg, 1.0 mmol, 1 equiv)
in THF (10 mL), and this reaction mixture was warmed to 50 8C. HCl
(37%, 3.00 g, 2.61 mL, 30 mmol, 30 equiv) was then added. The re-
action mixture was warmed to 50 8C for 2 h, and then concentrated
under reduced pressure. From the cooled aqueous solution pre-
cipitated a solid that was triturated and filtered. The obtained
crude 25 was purified by flash chromatography (CH2Cl2/iPrOH 9:1)
to give a white solid (160 mg, 46%): mp: 175–176 8C (dec. , EtOH/
EtOAc); 1H NMR (300 MHz, [D6]DMSO): d=1.49 (d,
3J=7 Hz, 3H,
CH3), 5.46 (s, 2H, CH2O), 5.52 (q,
3J=7 Hz, 1H, CH), 6.44 (s, 2H,
NH2), 7.05 (dd,
4J=2 Hz, 3J=9 Hz, 1H, H-5), 7.18 (s, 1H, H-3), 7.65
(d, 4J=2, 1H, H-7), 7.68 (d, 3J=9 Hz, 1H, H-4), 7.85, 8.50 (2 s, 2H, 4-
NH2CO-fx), 9.20 ppm (s, 1H, OH) ;
13C NMR (75 MHz, [D6]DMSO): d=
17.7, 52.2, 61.5, 106.4, 110.4, 114.2, 120.7, 123.8, 133.6, 140.2, 143.9,
154.8, 155.2, 155.6, 161.3 ppm; IR (KBr): n˜=3466, 3427, 3190,
1688,1670, 1572, 1469, 1443, 1265, 1219, 1153, 1067, 838,
776 cm1; MS (EI, 70 eV) m/z (%): 348 (35), 334 (60), 318 (95), 232
(50), 190 (82), 177 (100); Anal. calcd for C15H15N5O6S (393.38): C
45.80, H 3.84, N 17.80; found: C 45.81, H 4.03, N 17.53.
Leukotriene assay. Studies of 5-LO inhibition were carried out by
following a procedure similar to that reported previously.[30] Blood
samples were obtained from healthy volunteers who had not
taken any drug for at last two weeks. Volunteers gave their in-
formed and signed consent to the use of blood samples for re-
search purposes. Methanolic solutions of the tested compounds at
various concentrations were prepared, 10 mL aliquots were distrib-
uted in incubation polystyrene tubes, and the solvent was evapo-
rated. The residues were dissolved by vortexing in 1 mL hepari-
nized (20 IUmL1) venous blood, and the tubes were pre-incubated
for 15 min at 37 8C. Eicosanoid biosynthesis was initiated by
adding the calcium ionophore A23187 at 50 mm (final 0.05% v/v
DMSO) and terminated after 30 min by rapid cooling of the blood
in an ice bath and centrifuging at 3 8C for 10 min at 2500 g. Plasma
samples were further centrifuged at 12000 g at 3 8C for 3 min, and
then supernatants were ready to be tested for LTB4 production.
Basal LTB4 production in blood untreated with A23187 was sub-
tracted, and percent inhibition in samples incubated with tested
compounds was evaluated in comparison with control samples
with maximal LTB4 production. LTB4 production was evaluated by
competitive ELISA according to specific instructions provided by
Cayman Chemical, based on a competition between LTB4 and an
LTB4–acetylcholinesterase conjugate (LTB4 tracer). At the end of an
overnight incubation at 4 8C the amount of tracer (added in each
well at a constant concentration) bound to antiserum is inversely
proportional to the added concentrations of LTB4, produced by 5-
LO. This antibody–LTB4 complex binds to an unspecific antibody
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that had been previously attached to the well. The plate is washed
to remove any unbound reagents, and then Ellman’s reagent,
which contains a substrate for acetylcholinesterase, is added to the
well. The product of this enzymatic reaction gives a distinct yellow
color that absorbs at l 405 nm. The intensity of this color, deter-
mined spectrophotometrically, is proportional to the amount of
LT–tracers present in the well, which is inversely proportional to
the amount of LTs present in the well during the incubation. A
standard curve with known concentrations of LTB4 is used to
obtain concentrations in the sample wells. Percent inhibition in
compound-treated samples was calculated by comparison with
control untreated samples. The concentration of the tested com-
pounds effecting 50% inhibition (IC50) was calculated from the con-
centration–inhibition response curve (3–4 experiments).
Myorelaxing activity. Tracheas and aortas were isolated from male
Wistar rats weighing 180–200 g. The animals, treated humanely in
accordance with recognized guidelines on experimentation, were
anesthetized with CO2 and killed by decapitation. As few animals
as possible were used. The purposes and the protocols of our stud-
ies were approved by the Ministero della Salute, Rome (Italy). The
tissues were mounted in organ baths containing 30 mL Krebs-bi-
carbonate buffer of the following composition (mm): NaCl 111.2,
KCl 5.0, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.0, NaHCO3 12, glucose 11.1.
The solution was maintained at 37 8C and continuously gassed
with 95% O2/5% CO2 (pH 7.4). The tracheal tube was quickly ex-
cised and cleaned free of excess tissues, then was cut into single
rings. Three to four rings were joined together by thread to form a
chain and mounted under tension (1.0 g) in organ baths. After an
equilibration period of 120 min, 1 mm carbachol was added to the
organ bath to induce a spasm of the trachea rings, and when a
constant level was reached, cumulative concentration–response
curves to compounds were determined. Effects of 10 mm ODQ
were evaluated in a separate series of experiments in which it was
added 20 min before the contraction. With this protocol, the inhibi-
tor is pre-incubated for at least 40 min before the start of the
curve. Results are expressed as EC50SE (mm) ; EC50 values are the
mean of 4–6 determinations. Responses were recorded by an iso-
metric transducer connected to the MacLab System PowerLab.
Vasodilator activity. The aorta endothelium was removed and the
vessels were cut helically: three strips were obtained from each
aorta. The tissues were mounted under tension (1.0 g) in organ
baths. The aortic strips were allowed to equilibrate for 120 min
and then contracted with 1 mm phenylephrine. When the response
to the agonist reached a plateau, cumulative concentrations of the
vasodilating agent were added. The effects of 1 mm ODQ on relaxa-
tion were evaluated in separate series of experiments in which it
was added 5 min before the contraction. With this protocol, the in-
hibitor is pre-incubated for at least 30 min before the addition of
the vasodilator compound. Results are expressed as EC50SE (mm) ;
EC50 values are the mean of 4–8 determinations.
Anti-inflammatory activity. The anti-inflammatory activity of com-
pounds under study was tested by carrageenan-induced paw
edema in conscious rats. Acute edema was induced in the right
hind paw of rats by injecting into the plantar region 0.1 mL of
freshly prepared solution of 1% carrageenan. The volume of the
paw was measured using a plethysmograph (Basile, Italy) at 2, 3, 4,
and 5 h after carrageenan challenge. Inflammation was expressed
as the percentage change in paw volume.[31] Compounds under
study were administered intragastrically (i.g.) in a volume of
10 mLkg1 immediately before carrageenan injection.
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